- Van Dis, Erik;
- Sogi, Kimberly M;
- Rae, Chris S;
- Sivick, Kelsey E;
- Surh, Natalie H;
- Leong, Meredith L;
- Kanne, David B;
- Metchette, Ken;
- Leong, Justin J;
- Bruml, Jacob R;
- Chen, Vivian;
- Heydari, Kartoosh;
- Cadieux, Nathalie;
- Evans, Tom;
- McWhirter, Sarah M;
- Dubensky, Thomas W;
- Portnoy, Daniel A;
- Stanley, Sarah A
There are a limited number of adjuvants that elicit effective cell-based immunity required for protection against intracellular bacterial pathogens. Here, we report that STING-activating cyclic dinucleotides (CDNs) formulated in a protein subunit vaccine elicit long-lasting protective immunity to Mycobacterium tuberculosis in the mouse model. Subcutaneous administration of this vaccine provides equivalent protection to that of the live attenuated vaccine strain Bacille Calmette-Guérin (BCG). Protection is STING dependent but type I IFN independent and correlates with an increased frequency of a recently described subset of CXCR3-expressing T cells that localize to the lung parenchyma. Intranasal delivery results in superior protection compared with BCG, significantly boosts BCG-based immunity, and elicits both Th1 and Th17 immune responses, the latter of which correlates with enhanced protection. Thus, a CDN-adjuvanted protein subunit vaccine has the capability of eliciting a multi-faceted immune response that results in protection from infection by an intracellular pathogen.